• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . Clinical profile of bloodstream infections in COVID-19 patients: a retrospective cohort study

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2021 Sep 8;21(1):933.
doi: 10.1186/s12879-021-06647-x.
Clinical profile of bloodstream infections in COVID-19 patients: a retrospective cohort study


Naveenraj Palanisamy[SUP] 1 [/SUP], Nakka Vihari[SUP] 1 [/SUP], Durga Shankar Meena[SUP] 2 [/SUP], Deepak Kumar[SUP] 1 [/SUP], Naresh Midha[SUP] 1 [/SUP], Vibhor Tak[SUP] 3 [/SUP], Ankur Sharma[SUP] 4 [/SUP], Gopal Krishana Bohra[SUP] 1 [/SUP], Nikhil Kothari[SUP] 4 [/SUP], Naveen Dutt[SUP] 5 [/SUP], Pradeep Kumar Bhatia[SUP] 4 [/SUP], Mahendra Kumar Garg[SUP] 1 [/SUP], Sanjeev Misra[SUP] 6 [/SUP]



Affiliations

Abstract

Background: Bloodstream infections (BSIs) are an emerging cause of significant morbidity and mortality in severe Coronavirus disease 2019 (COVID-19). We aimed to assess the prevalence, clinical profile and outcome of BSIs in critically ill COVID-19 patients.
Methods: This was a single-centre retrospective study conducted at a tertiary care hospital in Western India. All patients (age > 18 years) with reverse-transcription polymerase chain reaction (RT-PCR) confirmed COVID-19 admitted in the intensive care unit (ICU) were included. Hospital electronic records were searched for demographic data, time of bloodstream infection since admission, clinical profile, antimicrobial resistance pattern and clinical outcome of all patients who developed BSIs.
Results: Out of 750 patients admitted in COVID ICU, 8.5% developed secondary BSIs. All severe COVID-19 patients who developed BSIs succumbed to illness. A significant proportion of BSIs were Gram-negative pathogens (53/64, 82.8%). Acinetobacter baumannii was the commonest isolate, followed by Klebsiella pneumoniae (32.8% and 21.9%, respectively). Multidrug-resistance organisms (MDRO) were found in 57.8% of the cases. The majority of MDRO belonged to K. pneumoniae and Enterococcus groups. The proportion of Gram-negative bacteria resistant to carbapenems was 47.2% (25/53). On multivariate analysis, raised total leukocyte counts, mechanical ventilation and presence of comorbidities were significantly associated with the incidence of BSIs.
Conclusion: We found a significant prevalence of Acinetobacter baumannii in COVID-19 associated BSIs. The presence of comorbidities raised leukocyte counts and mechanical ventilation should alarm clinicians for possible BSIs. The timely initiation of empirical antibiotics and rapid de-escalation is vital to improve the outcome. At the same time, strict compliance of infection control practices should be accomplished to reduce the occurrence of MDRO.

Keywords: Acinetobacter baumannii; Antimicrobial resistance; BSIs; COVID-19; ICU; Pneumonia.
 
Back
Top Bottom